Q-omics provides the consensus-scored MIR6165 profile across patient tissues and cancer cell-line models. MIR6165 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MIR6165 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR6165 RNA expression shows 9,566 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CHOL, BRCA, and THYM as cancer lineages where MIR6165 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6165 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6165 survival associations across molecular data types. MIR6165 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6165 RNA expression–survival associations across cancer types. High MIR6165 expression shows unfavorable associations in CHOL, MESO, LUSC and UVM, but favorable associations in HNSC and CESC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for MIR6165 RNA expression.
This table summarizes MIR6165 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6165. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6165 shows lower tumor expression in BRCA and higher tumor expression in LUSC, THCA and HNSC. The BRCA box plot shows higher MIR6165 RNA expression in normal versus tumor tissue (log2 FC = −0.549, t-test p < 0.001).
This table shows molecular features associated with MIR6165 in patient tissues and cancer cell lines. In patient samples, MIR6165 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
